Sharekhan's research report on Gland Pharma
Gland reported another weak quarter in Q2FY23 affected by muted performance across geographies. Core markets marginally grew by 3%, RoW declined by 3% while India business was down by 42% y-o-y which led to 3% y-o-y decline in revenue to Rs. 1,044.4 crore. Gross/EBITDA margins fell by 124/644 bps y-o-y impacted by decline in revenue, unfavourable geography and product mix, pricing pressures in some products and higher employee expenses. PAT declined by 20.2% y-o-y to Rs. 241.2 crore. Despite near-term headwinds due volume decline in the US and cost inflation, the medium-term prospects are intact led by a strong product pipeline and entry into newer markets.
Outlook
Stock has corrected by 41% in the past six months and currently trades at 29.8x/23.6x its FY2023E/FY2024E EPS, which factors in near-term headwinds. We retain a Buy recommendation on Gland Pharma (Gland) with a revised PT of Rs. 2,260.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.